Tenaya Therapeutics Inc (TNYA NASDAQ) stock market data APIs
$0.7329
0.03(4.1%)
as of June 5, 2026
Try our APIs with
free plan!
Tenaya Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Prev. Close
0.7329
Open
0.7647
High
0.7665
Low
0.7118
52 wk Range
0.5316-2.35
Market Cap
158 M
Shares Outstanding
217 M
Revenue
225 K
EPS
-0.09
Beta
2.821
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tenaya Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tenaya Therapeutics Inc data using free add-ons & libraries
Get Tenaya Therapeutics Inc Fundamental Data
Tenaya Therapeutics Inc Fundamental data includes:
- Net Revenue: 225 K
- EBITDA: -78 320 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tenaya Therapeutics Inc News
New
Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) announced new interim data from its ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic...
Tenaya To Present Interim Data From MyPEAK-1 Trial In MYBPC3-Associated HCM Today; Stock Up
(RTTNews) - Tenaya Therapeutics, Inc. (TNYA) announced that it will present new interim data today from Cohort 1 and Cohort 2 of the ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, its gene thera...
High Growth Tech Stocks To Watch In The US May 2026
The market in the United States has been flat over the last week but is up 27% over the past year, with earnings forecast to grow by 17% annually. In such a dynamic environment, identifying high growt...
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies ...
Get Tenaya Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
